文献速递临床试验与 GCP流行病学与生物统计

口服阿奇霉素对SARS-CoV-2感染门诊患者症状的影响:随机临床试验

Effect of Oral Azithromycin vs Placebo on COVID-19 Symptoms in Outpatients With SARS-CoV-2 Infection: A Randomized Clinical Trial.
PubMed 文献 · JAMA · 2021-01-01

该随机临床试验纳入263例未住院的SARS-CoV-2感染门诊患者,按2:1随机接受单剂口服阿奇霉素1.2 g或安慰剂。因 interim 分析无效,试验被数据与安全监查委员会提前终止。

要点

  • 单剂口服阿奇霉素1.2 g未提高门诊SARS-CoV-2感染者第14天无症状比例。
  • 结果不支持门诊SARS-CoV-2感染常规使用阿奇霉素。

核心结论

  • 在SARS-CoV-2感染门诊患者中,与安慰剂相比,单剂阿奇霉素未使第14天无症状的可能性更大。
  • 这些发现不支持门诊SARS-CoV-2感染常规使用阿奇霉素。

研究设计与样本

  • 随机双盲安慰剂对照临床试验,2020年5月至2021年3月在美国通过互联网远程入组门诊患者。
  • 纳入年龄≥18岁、入组前7天内SARS-CoV-2诊断检测(核酸扩增或抗原)阳性且入组时未住院者。
  • 共筛查604人,排除297人不合格、44人拒绝,最终随机263人;按2:1分为阿奇霉素组171例和安慰剂组92例。
  • 干预为单剂口服阿奇霉素1.2 g或匹配安慰剂;主要终点为第14天自报COVID-19症状消失。

主要发现

  • 263例随机参与者中位年龄43岁,174例(66%)为女性,57%为非西班牙裔白人,29%为拉丁裔/西班牙裔;76%完成试验。
  • 23个预设次要临床终点中18个无显著差异。
  • 试验因 interim 分析显示无效,被数据与安全监查委员会提前终止。

临床怎么用

  • 门诊SARS-CoV-2感染者不应常规使用单剂阿奇霉素治疗。

局限性

  • 试验因无效提前终止,样本量263例,可能影响次要终点如住院的统计效能。
  • 仅76%参与者完成试验,存在失访偏倚可能。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Azithromycin has been hypothesized to have activity against SARS-CoV-2. OBJECTIVE: To determine whether oral azithromycin in outpatients with SARS-CoV-2 infection leads to absence of self-reported COVID-19 symptoms at day 14. DESIGN, SETTING, AND PARTICIPANTS: Randomized clinical trial of azithromycin vs matching placebo conducted from May 2020 through March 2021. Outpatients from the US were enrolled remotely via internet-based surveys and followed up for 21 days. Eligible participants had a positive SARS-CoV-2 diagnostic test result (nucleic acid amplification or antigen) within 7 days prior to enrollment, were aged 18 years or older, and were not hospitalized at the time of enrollment. Among 604 individuals screened, 297 were ineligible, 44 refused participation, and 263 were enrolled. Participants, investigators, and study staff were masked to treatment randomization. INTERVENTIONS: Participants were randomized in a 2:1 fashion to a single oral 1.2-g dose of azithromycin (n = 171) or matching placebo (n = 92). MAIN OUTCOMES AND MEASURES: The primary outcome was absence of self-reported COVID-19 symptoms at day 14. There were 23 secondary clinical end points, including all-cause hospitalization at day 21. RESULTS: Among 263 participants who were randomized (median age, 43 years; 174 [66%] women; 57% non-Hispanic White and 29% Latinx/Hispanic), 76% completed the trial. The trial was terminated by the data and safety monitoring committee for futility after the interim analysis. At day 14, there was no significant difference in proportion of participants who were symptom free (azithromycin: 50%; placebo: 50%; prevalence difference, 0%; 95% CI, -14% to 15%; P > .99). Of 23 prespecified secondary clinical end points, 18 showed no significant difference. By day 21, 5 participants in the azithromycin group had been hospitalized compared with 0 in the placebo group (prevalence difference, 4%; 95% CI, -1% to 9%; P = .16). CONCLUSIONS AND RELEVANCE: Among outpatients with SARS-CoV-2 infection, treatment with a single dose of azithromycin compared with placebo did not result in greater likelihood of being symptom free at day 14. These findings do not support the routine use of azithromycin for outpatient SARS-CoV-2 infection. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04332107.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Oldenburg CE, Pinsky BA, Brogdon J, et al. Effect of Oral Azithromycin vs Placebo on COVID-19 Symptoms in Outpatients With SARS-CoV-2 Infection: A Randomized Clinical Trial. JAMA. 2021. PMID: 34269813. doi:10.1001/jama.2021.11517

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。